New drug aims to stop kidney disease relapses
NCT ID NCT07499700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called BAT4406F in people with two rare kidney conditions: Minimal Change Disease and Focal Segmental Glomerulosclerosis. The goal is to see if it can reduce protein in the urine and prevent the disease from coming back. About 192 participants will receive either the drug or a placebo by IV infusion, and researchers will track their progress over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAT4406F injection
What this could lead to
If it works, this could offer a new treatment option to control protein leakage and reduce relapses in people with MCD or FSGS.
What could go wrong
This is an early-to-mid-stage trial with only 192 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL CHANGE DISEASE (MCD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China